摘要:
The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.
摘要:
The invention relates to a metallocene complex according to formula 1
wherein M is a metal selected from lanthanides or transition metals from group 3, 4, 5 or 6 of the Periodic System of the Elements, Q is an anionic ligand to M, X is a cyclic bridging group that is bonded to a carbon atom of the cyclopentadienyl ligand and to nitrogen, Z 1 , Z 2 , Z 3 and Z 4 are identical or different and can be chosen from hydrogen or a hydrocarbon radicals; adjacent substituents Z can form a ring, R is chosen from hydrogen or a hydrocarbon radical with 1-20 carbon atoms. Also claimed are compositions comprising the metallocene complex, a process for the preparation of said complex and a process for the polymerization of olefin polymers in the presence of the metallocene complex. A particular embodiment is the following complex:
摘要:
Provided is a method for producing a 2-alkenylamine compound efficiently and at low cost, using a primary or secondary amine compound and a 2-alkenyl compound as the starting materials therefor. The 2-alkenyleamine compound is produced by 2-alkenylating a primary or secondary amine compound, using a specified 2-alkenylating agent and in the presence of a catalyst comprising a complexing agent and a transition metal precursor stabilized by a monovalent anionic five-membered conjugated diene.
摘要:
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-choIesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides and accordingly to treat diseases which are affected by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in certain mammals (i.e., those which have CETP in their plasma), including humans: wherein A, B, C, R1 and R14 are described herein.
摘要:
This present invention provides for cholesteryl ester transfer protein (CETP) inhibitors, of formula Ia and Ib / pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein (HDL)-choIesterol and to lower certain other plasma lipid levels, such as low density lipoprotein (LDL)-cholesterol and triglycerides and accordingly to treat diseases which are affected by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in certain mammals (i.e., those which have CETP in their plasma), including humans: wherein A, B, C, R1 and R14 are described herein.
摘要:
The present invention relates to a process for the preparation of compounds of formula wherein R1, R2 and R3 are each independently of the others hydrogen or C1-C4alkyl, by a) reacting compounds of formula (II) wherein R1, R2 and R3 are as defined for formula (I) and X is bromine or chlorine, with a compound of formula (III) wherein R4 is hydrogen or C1-C4alkyl, in the presence of a base and catalytic amounts of at least one palladium complex compound, to form compounds of formula (IV) wherein R1, R2, R3 and R4 are as defined for formula (I), and b) converting those compounds, using a reducing agent, into compounds of formula (I).
摘要:
Compounds represented by the general formula (I) or (II) or salts or solvates thereof, which are useful in the diagnosis, prevention, and/or treatment of diseases with accumulation of prion protein or in specific staining of prion protein contained in a specimen.
摘要:
A novel triphenylphosphine derivative which is synthesized from triphenylphosphine and a hydroxylated lactone; a palladium/nickel complex having the derivative as a ligand; and a process for producing a biaryl derivative which comprises using this complex as a catalyst. By the use of the complex as a catalyst, the target reaction product can be easily separated from the catalyst or the phosphorus compound. Thus, the biaryl derivative can be synthesized in good yield.
摘要:
Chiral ligands and transition metal complexes based on such chiral ligands useful in asymmetric catalysis are disclosed. The chiral ligands include phospholanes, P, N ligands, N, N ligands, biphenols, and chelating phosphines. The ferrocene-based irridium (R,R)-f-binaphane complex reduces imines to the corresponding amines with 95-99.6 % enantioselectivity and reduces β-substituted-α-arylenamides with 95 % enantioselectivity. The transition metal complexes of the chiral ligands are useful in asymmetric reactions such as asymmetric hydrogenation of imines, asymmetric hydride transfer reactions, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, allylic alkylation, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition and epoxidation reactions.